# Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

> **NCT01029886** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 912 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide once weekly
- **DRUG:** liraglutide

## Key facts

- **NCT ID:** NCT01029886
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-01
- **Final completion:** 2011-04
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2015-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029886, "Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01029886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*